Adenocarcinoma of the oesophagus and oesophagogastric junction

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

5FDA treatments

17Recruiting trials

Regulatory Watchboard

10 events

Jun 2026A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

University Hospital, Antwerp — NA

TrialNOT YET RECRUITING

Apr 2026Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Abramson Cancer Center at Penn Medicine — PHASE2

TrialNOT YET RECRUITING

Mar 2026A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb — PHASE2, PHASE3

TrialRECRUITING

Feb 2026Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

I-Mab Biopharma US Limited — PHASE2

TrialRECRUITING

Dec 2025A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — PHASE1

TrialRECRUITING

Dec 2025Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Universitaire Ziekenhuizen KU Leuven — PHASE2

TrialRECRUITING

Dec 2025First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Plexium, Inc. — PHASE1

TrialRECRUITING

Sep 2025Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Second Affiliated Hospital, School of Medicine, Zhejiang University — NA

TrialNOT YET RECRUITING

Sep 2025Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

Erasmus Medical Center — PHASE2

TrialRECRUITING

Sep 2025Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

Centre Leon Berard — PHASE2

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

4 programs

FINANCIAL LANDSCAPE SUMMARY

4

Total programs

4

Open now

Patient Assistance Programs4

Enhertu

Daiichi Sankyo, Inc.

OpenContact for detailsApply ↗

Herceptin

Genentech, Inc.

OpenContact for detailsApply ↗

Tevimbra

BeOne Medicines USA, Inc.

OpenContact for details

LONSURF

Taiho Oncology, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Tevimbra

(tislelizumab-jsgr)Orphan drug

BeOne Medicines USA, Inc.

Programmed Death Receptor-1 Blocking Antibody [EPC]

12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokin...

Approved Dec 2024FDA label ↗

Enhertu

(fam-trastuzumab deruxtecan-nxki)Orphan drug

Daiichi Sankyo, Inc.

12.1 Mechanism of Action Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The s...

Approved Jan 2021FDA label ↗

LONSURF

(trifluridine/tipiracil)Orphan drug

Taiho Oncology, Inc.

Nucleoside Analog Antiviral [EPC]

12.1 Mechanism of Action LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, ...

Approved Feb 2019FDA label ↗

Herceptin

(trastuzumab)Orphan drug

Genentech, Inc.

HER2/neu Receptor Antagonist [EPC]

12.1 Mechanism of Action The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to th...

Approved Oct 2010FDA label ↗

Vyloy

(zolbetuximab-clzb)Orphan drugstandard

Astellas Pharma Global Development Inc.

Claudin 18.2-directed Cytolytic Antibody [EPC]

12.1 Mechanism of Action Zolbetuximab-clzb is a claudin 18.2 (CLDN18.2)-directed cytolytic antibody that depletes CLDN18.2-positive cells via antibody...

View full treatment details on disease page →

Clinical Trial Landscape

17 active trials

7Phase 2

3Phase 1

1N/A

1Unknown

5PHASE1, PHASE2

17Total recruiting

Search clinical trials for Adenocarcinoma of the oesophagus and oesophagogastric junction →

Recent News & Research

No recent news articles indexed yet for Adenocarcinoma of the oesophagus and oesophagogastric junction.
Search PubMed for Adenocarcinoma of the oesophagus and oesophagogastric junction →

Browse all Adenocarcinoma of the oesophagus and oesophagogastric junction news →

Specialist Network

Top 6 by expertise

Global Clinical Leader

Daiichi Sankyo

Score 3644 trials4 pubs

Manuel Häckl, MD

Basilea Pharmaceutica International Ltd, Allschwil

Score 185 trials

Howard Safran, MD, M.D

BrUOG

📍 PROVIDENCE, RI

Score 99 trials

Michael Cecchini, DPT

Yale University Cancer Center LAO

📍 BEL AIR, MD

Score 62 trials10 pubs

Syma Iqbal, MD, M.D

University of Southern California

📍 LOS ANGELES, CA

Score 43 trials

Executive Director

Astellas Pharma Global Development, Inc.

Score 42 trials

View all Adenocarcinoma of the oesophagus and oesophagogastric junction specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles